Tag Archives: Leica Biosystems

December 2023—While many dismiss the saying “Nothing lasts forever” with a simple shrug, those three words may cause angst in those anticipating the demise of their laboratory information system.

Nov. 13, 2023—Leica Biosystems has released three software features that aim to improve image quality and flexible scanning solutions in research settings for its Aperio GT 450 digital pathology scanner.

July 24, 2023—HNL Lab Medicine announced it has selected solutions from Proscia and Leica Biosystems to establish an advanced digital pathology practice.

July 2023—Leica Biosystems launched its Bond ChromoPlex II Dual Detection kit for use in immunohistochemistry and chromogenic in situ hybridization on Bond-Max and Bond-III instruments.

June 9, 2023—Leica Biosystems launched its Bond ChromoPlex II Dual Detection kit for use in immunohistochemistry and chromogenic in situ hybridization on Bond-Max and Bond-III instruments.

April 2023—Leica Biosystems announced FDA 510(k) clearance of the Bond mismatch repair antibody panel for use in screening patients who have colorectal cancer for the identification of Lynch syndrome. The panel is for in vitro diagnostic use on Leica’s Bond-III and Bond-Max immunohistochemistry automated instruments. Turnaround time is 2.5 hours on the Bond-III and about 3.5 hours on the Bond-Max.  

April 2023—At the medical center of the University of Medicine and Pharmacy at Ho Chi Minh City, patients are not screened for bladder cancer using urine cytology because the pathology department does not have the capability for such screening. But that may soon change, thanks to an organization focused on using digital pathology to increase the availability of pathology education resources in developing countries.

April 3, 2023—Leica Biosystems announced FDA 510(k) clearance of the Bond mismatch repair antibody panel for use in screening patients with colorectal cancer for the identification of Lynch syndrome.

May 31, 2022—Leica Biosystems launched Bond-Prime, a high-speed immunohistochemistry and in situ hybridization staining platform.

June 2020—The global market for health care chatbots has been growing at a fairly rapid pace in recent years, but “COVID-19 is the thing that’s going to make chatbots mainstream,” says Greg Kefer, chief marketing officer at the chatbot company LifeLink Health. A 2019 Allied Market Research report, released just months prior to the COVID-19 pandemic, projected the health care chatbot industry would reach $345.3 million by 2026, a steep rise from 2018, when it garnered $116.9 million (www.allied​market​research.​com/healthcare-chatbots-market). But now, the COVID-19 pandemic has put into sharp relief one of the key value propositions of chatbots—unlimited scale, which means the timeline for adoption “just got massively compressed,” says Kefer, whose software-as-a-service company develops enterprise-level chatbots for large health care organizations.

May 4, 2020—Leica Biosystems announced it has received additional notification from the FDA about its intention to exercise enforcement discretion when the Aperio WebViewer, a web-based viewing software within Aperio eSlide Manager

April 2020—Leica Biosystems launched the Aperio GT 450, its next-generation digital pathology scanner. The research-use-only Aperio GT 450 offers continuous rack loading with priority scanning and takes 32 seconds to scan a 15 mm × 15 mm tissue area on a pathology slide at 40× magnification with a throughput of 81 slides per hour. The system’s slide racks are compatible with other Leica Biosystems products.

April 9, 2020—Leica Biosystems has received notification from the FDA that its Aperio ImageScope DX Viewer with images acquired on the Aperio AT2 DX Scanner can be used for remote diagnosis under emergency use.

June 11, 2019–Leica Biosystems received clearance from the Food and Drug Administration to market its Aperio AT2 DX System for clinical diagnosis in the United States.

February 2019—Leica Biosystems launched a programmed death-ligand 1 antibody. The PD-L1 1 (73-10) monoclonal antibody is intended to be used for the qualitative identification by light microscopy of endogenous PD-L1 protein in formalin-fixed, paraffin-embedded tissue by immunohistochemical staining using the company’s fully automated Bond system.

January 2019—Leica Biosystems has partnered with Ultivue to co-market Ultivue’s Ulti­Mapper assays with Leica’s Bond Rx research staining platform.

September 2018—Leica Biosystems introduced the Bond Rx next-generation research stainer. The system offers greater flexibility when optimizing conditions for a variety of test types including immunofluorescence, immunohistochemistry, fluorescence in situ hybridization, tyramide signal amplification, multiplexing, and other emerging tests.

July 26, 2018—Leica Biosystems introduced the Bond Rx next-generation research stainer. The new system offers greater flexibility when optimizing conditions for a variety of test types including immunofluorescence, immunohistochemistry, fluorescence in situ hybridization, tyramide signal amplification, multiplexing, and other emerging tests. Bond Rx allows users to customize dewax options, choose from six probe application and removal protocols, and select the ...

September 2016—Leica Biosystems added four sizes of Surgipath AffirmSeal jars. The new sizes, 40 mL, 60 mL, 90 mL, and 120 mL, are offered in multiple packaging configurations. Prefilled with 10 percent neutral buffered formalin, the jars are specifically designed for safe collection and transport of various sized specimens.

August 2016—Document-management systems worthwhile if you go extra mile; HHS releases guidance on ransomware attacks; McKesson alters IT business; Leica sample-tracking system added to Psyche products; Agilent buys iLab Solutions

May 2016—Leica Biosystems introduced the Aperio Versa, a combination digital pathology research scanner for bright-field, fluorescence, and FISH imaging. High levels of automation and an optional 200-slide autoloader enable unsupervised batch processing, from low magnification to high resolution, oil-immersion scanning.

April 2016—Leica Biosystems and Advanced Cell Diagnostics announced a comprehensive partnership to develop and commercialize tissue-based diagnostic tests based on ACD’s RNAscope in situ hybridization assays on Leica’s Bond clinical advanced staining instruments.

November 2015—Leica Biosystems released its HistoCore Arcadia, a modular embedding system designed to streamline workflow in histopathology laboratories. HistoCore Arcadia is a combination of the paraffin-dispensing module Arcadia H and the cold plate Arcadia C. Simple operation and precise control help improve the quality, reliability, and speed of embedding work. The new station incorporates wrist pads for increased comfort and stability, an optional magnifier to facilitate specimen orientation of small and complex biopsies, and an LCD touchscreen.

June 2015—APiQ (Anatomic Pathology with Extra Intelligence) from Leica provides real-time laboratory workflow information on mobile devices. The initial release consists of two immunohistochemistry solutions: the APiQ Inventory Manager and the APiQ Instrument Dashboard.

January 2015—Leica Biosystems has completed its acquisition of Devicor Medical Products. The Cincinnati-based company has annual revenues of approximately $170 million and more than 550 employees.

November 2014—Leica Biosystems and Advanced Cell Diagnostics announced the comarketing of ACD’s RNAscope LS ISH assays using Leica’s Bond Rx research-use-only staining platform.

June 2014—Leica Biosystems joined the GHX electronic trading exchange for U.S. customers. The GHX Exchange enables provider organizations to send their electronic data interchange (EDI) transactions through a single connection as opposed to multiple point-to-point EDI connections, thus allowing Leica’s customers to view their transactions and address discrepancies in real time.

February 2014—Leica Biosystems announced a partnership with EyesFinder, a developer of visual search technology, to create decision support tools for pathologists.

Leica Biosystems has signed an agreement to supply HealthTrust, a group purchasing organization and provider of total cost management solutions for health care facilities, with its broad range of histology instrumentation, laboratory consumables, and sample-tracking systems.

Leica Biosystems, in partnership with Indica Labs, has launched the HALO next-generation image-analysis software. The HALO platform is fast, scalable, and user-friendly and is for Aperio ePathology image analysis.